Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Cash & Equivalents (2018 - 2025)

Revolution Medicines has reported Cash & Equivalents over the past 8 years, most recently at $383.7 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $383.7 million for Q4 2025, down 29.34% from a year ago — trailing twelve months through Dec 2025 was $383.7 million (down 29.34% YoY), and the annual figure for FY2025 was $383.7 million, down 29.34%.
  • Cash & Equivalents for Q4 2025 was $383.7 million at Revolution Medicines, up from $217.4 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for RVMD hit a ceiling of $696.1 million in Q4 2023 and a floor of $97.7 million in Q1 2022.
  • Median Cash & Equivalents over the past 5 years was $282.1 million (2024), compared with a mean of $291.8 million.
  • Biggest five-year swings in Cash & Equivalents: soared 715.82% in 2021 and later crashed 72.22% in 2022.
  • Revolution Medicines' Cash & Equivalents stood at $108.5 million in 2021, then skyrocketed by 48.77% to $161.4 million in 2022, then skyrocketed by 331.29% to $696.1 million in 2023, then decreased by 21.99% to $543.1 million in 2024, then decreased by 29.34% to $383.7 million in 2025.
  • The last three reported values for Cash & Equivalents were $383.7 million (Q4 2025), $217.4 million (Q3 2025), and $402.4 million (Q2 2025) per Business Quant data.